: Partnering with the University of Melbourne, they have achieved over 99.9% accuracy in reconstructing the thylacine genome. The Technology "Toolkit"

In October 2024, the company launched the Colossal Foundation , a non-profit dedicated to applying these technologies to today's endangered species. They are currently working on a vaccine for a deadly elephant virus (EEHV) and biobanking the "top 100" most imperiled species to ensure their genetic survival.

Colossal aims to restore ecological balance by reintroducing "keystone" species to their original habitats. By reviving these animals, they hope to slow climate change—for example, by having woolly mammoths restore the Arctic grasslands to prevent permafrost melt.